MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

51.58 +0.62 (+1.22%)
Official Closing Price Updated: 7:00 PM EDT, Jul 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
3 Beaten-Down Stocks With GLP-1 Exposure to Buy and Hold ↗
They may profit from the rapidly growing GLP-1 market in very different ways. 
Via The Motley Fool
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients ↗
Will this pharma company become a new leader in the weight loss market? 
Via The Motley Fool
News headline image
Where Will Novo Nordisk Stock Be in 3 Years? ↗
Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while. 
Via The Motley Fool
News headline image
Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors? ↗
Novo Nordisk is accusing Eli Lilly of deceptive advertising about GLP-1 drugs. 
Via The Motley Fool
Topics Lawsuit
News headline image
2 Top Growth Stocks to Buy Right Now Without Any Hesitation ↗
There are plenty of reasons to love these companies. 
Via The Motley Fool
News headline image
3 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗
With yields like this, these undervalued tickers aren't apt to remain this cheap forever. 
Via The Motley Fool
Topics Lawsuit
News headline image
"Deceptive Advertising!" Claims Novo Nordisk in Explosive New GLP-1 Lawsuit Against Eli Lilly. Here's What That Means for Both Stocks. ↗
Novo Nordisk is also demanding that Eli Lilly pull its ads and pay damages. 
Via The Motley Fool
Topics Lawsuit
News headline image
Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing ↗
Novo Nordisk is offering an attractive 3.5% yield backed by a business where volume is the new focus. 
Via The Motley Fool
News headline image
Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:NVO),(NASDAQ:SNY),(NASDAQ:DXCM),(NASDAQ:TNDM) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Could Pfizer Ultimately Be the Biggest Winner in the $100 Billion Weight-Loss Market? ↗
It is definitely a strong contender. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 ↗
Viking's latest program seeks to push the envelope in weight loss efficacy. 
Via The Motley Fool
News headline image
The Most Overlooked Reason Eli Lilly Stock Keeps Surging -- and It Has Nothing to Do With Weight Loss ↗
There's a good reason why investors are focused on Eli Lilly's GLP-1 business, but there's more going on at the company. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Wegovy Pill Just Changed the GLP-1 Market. Here's Why Eli Lilly Stock Could Still Win ↗
Novo Nordisk is finally getting one up on its biggest rival. 
Via The Motley Fool
News headline image
3 High-Yield Dividend Stocks to Buy and Hold ↗
All three can be bought on the dip. 
Via The Motley Fool
Topics Intellectual Property
News headline image
This GLP-1 Stock Could Double by 2030. Here's Why ↗
Investors need to ask tough questions before initiating a position in this biotech company. 
Via The Motley Fool
News headline image
2 Beaten-Down GLP-1 Stocks to Buy on the Dip ↗
Don't wait until clinical milestones send their share prices soaring. 
Via The Motley Fool
News headline image
Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market? ↗
Eyes are on the rollout of Lilly's new weight loss pill. 
Via The Motley Fool
News headline image
3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026 ↗
This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends. 
Via The Motley Fool
News headline image
Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗
There are good reasons to invest in Lilly and to hold off. 
Via The Motley Fool
News headline image
Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? ↗
So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off. 
Via The Motley Fool
News headline image
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week ↗
An accelerated approval for Agios' key drug to treat sickle cell disease appears to be on the cards. 
Via The Motley Fool
News headline image
Is It Too Late to Buy Eli Lilly? ↗
The stock has soared 400% in recent years. 
Via The Motley Fool
News headline image
Prediction: Eli Lilly Stock Will Hit This Price by the End of 2026 ↗
Eli Lilly's next leg of growth may have less to do with how well its weight loss drugs work and more to do with how many people can finally get them. 
Via The Motley Fool
News headline image
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom ↗
Don't sleep on these medical device leaders. 
Via The Motley Fool
Topics Supply Chain
News headline image
3 Reasons to Buy Novo Nordisk Stock ↗
The stock is down, but it isn't out yet. 
Via The Motley Fool
News headline image
U.S. Healthcare Spending Just Hit $5.7 Trillion and Continues to Grow: 2 Stocks to Buy to Profit From the Trend ↗
Good medical care will always be in high demand, which makes some healthcare stocks strong long-term picks. 
Via The Motley Fool
News headline image
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner ↗
Hims & Hers Health shares have surged 45% in 30 days on GLP-1 coverage shifts, but overbought technicals, a Hold rating, and rising short interest suggest a pullback may be near. 
Via MarketBeat
News headline image
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years? ↗
The weight-loss market is crowded, but this company's lead drug candidate has several key advantages. 
Via The Motley Fool
News headline image
Could Buying Eli Lilly Stock Today Set You Up for Life? (Hint: Yes.) ↗
Lilly offers investors safety and growth. 
Via The Motley Fool
News headline image
How Much Could $1,000 Invested in Viking Therapeutics Be Worth by 2030? ↗
This biotech might have a bright future, but it'll need to survive against the incumbents to do so. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story